Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Brexucabtagene autoleucel |
| Synonyms | |
| Therapy Description |
Tecartus (brexucabtagene autoleucel) are autologous T-cells engineered to express an anti-CD-19 chimeric antigen receptor (CAR), which may potentially target CD-19-expressing tumor cells (PMID: 32242358). Tecartus (brexucabtagene autoleucel) is FDA approved for use in adult patients with relapsed or refractory mantle cell lymphoma and patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Brexucabtagene autoleucel | Tecartus | KTE-X19|KTEX19|KTE X19 | Tecartus (brexucabtagene autoleucel) are autologous T-cells engineered to express an anti-CD-19 chimeric antigen receptor (CAR), which may potentially target CD-19-expressing tumor cells (PMID: 32242358). Tecartus (brexucabtagene autoleucel) is FDA approved for use in adult patients with relapsed or refractory mantle cell lymphoma and patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06287229 | Phase Ib/II | Brexucabtagene autoleucel Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Vincristine Sulfate | Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab | Recruiting | USA | 0 |
| NCT06144606 | Phase II | Brexucabtagene autoleucel | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting | USA | 0 |
| NCT06553872 | Phase II | Brexucabtagene autoleucel Brexucabtagene autoleucel + Pirtobrutinib Pirtobrutinib | Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Recruiting | USA | 0 |
| NCT06482684 | Phase II | Ibrutinib Ibrutinib + Rituximab Bendamustine + Ibrutinib + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Brexucabtagene autoleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma (CARMAN) | Recruiting | DEU | 0 |
| NCT05041309 | Phase II | KITE-585 KITE-222 Brexucabtagene autoleucel KITE-718 axicabtagene ciloleucel KITE-439 | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | Enrolling by invitation | USA | NLD | ISR | GBR | FRA | DEU | CAN | AUS | 1 |
CKB BOOST